Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silo Pharma, Inc. - Common Stock (NQ:SILO)

0.5620 -0.0951 (-14.47%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silo Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug
From Silo Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Final Preclinical Study for PTSD Treatment SPC-15
Via Investor Brand Network
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Secures USPTO Patent for PTSD Treatment SPC-15
Via Investor Brand Network
Topics Intellectual Property
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Provisional Patent for SPC-15 Dual-Action Treatment
Via Investor Brand Network
Topics Intellectual Property
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Early Data on SP-26 Ketamine Implant Study
Via Investor Brand Network
Topics Animal Testing
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Bolsters Intellectual Property with New Patent Filing for PTSD Treatment
Via Investor Brand Network
Topics Intellectual Property
Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Silo Pharma Shares Are Surging Today: What's Going On?
Silo Pharma Inc.'s stock (NASDAQ: SILO) is on the the rise Wednesday following the company's announcement that it has been awarded a U.S. patent for its PTSD treatment titled "Pharmacological... 
Via Benzinga
Topics Intellectual Property
Crude Oil Down 1%; US Weekly Jobless Claims Decline
 
Via Benzinga
US Stocks Down; Acuity Brands Posts Weak Revenue
 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Strengthens Patent Portfolio with Approval for PTSD Treatment SPC-15
Via Investor Brand Network
Topics Intellectual Property
Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances Ketamine Implant Development with Pharmacokinetic Study
Via Investor Brand Network
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partners with Kymanox to Advance Ketamine Implant Therapeutic for Chronic Pain
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why Is Silo Pharma Stock Gaining Today?
Silo Pharma stock is rising after announcing a collaboration with Kymanox to develop a subcutaneous insertion device for its SP-26 chronic pain treatment. 
Via Benzinga
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Promising Preclinical Results for SPC-15 in Treating Severe Psychiatric Disorders
Via Investor Brand Network
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Reports Promising Results from Testing of Ketamine-Loaded Implant for Chronic Pain Relief
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.